Abstract
Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30% of patients by five years. Once cirrhosis develops, the risk of hepatic decompensation is 42% per year. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation and a renewed interest in the role of anti-viral therapies. Despite encouraging results with pegylated interferon and ribavirin in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful for genotype 1 patients ( < 40%). Rejection although rare, remains a concern and the use of stimulating factors controversial. The lack of effective therapies, severe side effects and reports of hepatic decompensation despite HCV eradication raises the question of whether these patients should be treated with interferon-based therapies. Clinical trials of newer antivirals are urgently required in these patients who are at risk of rapid development of cirrhosis.
Keywords: Liver transplantation, hepatitis C, recurrenct viral hepatitis, HCV, liver disease, Immunosuppression, Calcineurin Inhibitors, Corticosteroids, viremia, Azathioprine, IL28B Polymorphisms
Anti-Infective Agents
Title: Recurrent Hepatitis C After Liver Transplantation
Volume: 10 Issue: 1
Author(s): Sandeep Mukherjee
Affiliation:
Keywords: Liver transplantation, hepatitis C, recurrenct viral hepatitis, HCV, liver disease, Immunosuppression, Calcineurin Inhibitors, Corticosteroids, viremia, Azathioprine, IL28B Polymorphisms
Abstract: Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30% of patients by five years. Once cirrhosis develops, the risk of hepatic decompensation is 42% per year. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation and a renewed interest in the role of anti-viral therapies. Despite encouraging results with pegylated interferon and ribavirin in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful for genotype 1 patients ( < 40%). Rejection although rare, remains a concern and the use of stimulating factors controversial. The lack of effective therapies, severe side effects and reports of hepatic decompensation despite HCV eradication raises the question of whether these patients should be treated with interferon-based therapies. Clinical trials of newer antivirals are urgently required in these patients who are at risk of rapid development of cirrhosis.
Export Options
About this article
Cite this article as:
Mukherjee Sandeep, Recurrent Hepatitis C After Liver Transplantation, Anti-Infective Agents 2012; 10 (1) . https://dx.doi.org/10.2174/2211362611201010034
DOI https://dx.doi.org/10.2174/2211362611201010034 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
Call for Papers in Thematic Issues
An Overview of Drugs for Multiple Targets and Variants of SARS-CoV-2 Through Artificial Intelligence, Machine Learning, Deep Learning, and Experimental Analysis
The emergence and rapid evolution of SARS-CoV-2 variants have posed significant challenges in the ongoing fight against the COVID-19 pandemic. The development of effective treatments for multiple viral targets and variants demands innovative approaches, including artificial intelligence (AI), machine learning (ML), and deep learning (DL) techniques. This special issue aims ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Quantum Dot-Based Nanoprobes for In Vivo Targeted Imaging
Current Molecular Medicine Antigene and Antiproliferative Effects of Triplex-Forming Oligonucleotide (TFO) Targeted on hmgb1 Gene in Human Hepatoma Cells
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Biological Evaluation of 2´-Hydroxy-4´,6´-Diprenyloxychal-Cone Derivatives as Potent CDC25B and PTP1B Inhibitors
Letters in Drug Design & Discovery Exploring Proteomic Drug Targets, Therapeutic Strategies and Protein - Protein Interactions in Cancer: Mechanistic View
Current Cancer Drug Targets Promising Protective Effects of Chrysin in Cardiometabolic Diseases
Current Drug Targets Targeted Tumor Therapies at a Glance
Current Drug Targets Pharmacophore Modeling and 3D QSAR Studies of Novel Human Carbonic Anhydrase IX Inhibitors
Letters in Drug Design & Discovery Modulators of Protein-Protein Interactions – Novel Approaches in Targeting Protein Kinases and Other Pharmaceutically Relevant Biomolecules
Current Topics in Medicinal Chemistry The Renin Angiotensin System in the Regulation of Angiogenesis
Current Pharmaceutical Design The HOX Gene Network as a Potential Target for Cancer Therapy
Current Cancer Therapy Reviews Pancreatic Cancer Metastasis: Are we being Pre-EMTed?
Current Pharmaceutical Design Novel HSP90 Inhibitor NVP-AUY922 Enhances the Anti-tumor Effect of Temsirolimus Against Oral Squamous Cell Carcinoma
Current Cancer Drug Targets Dynamic Changes in Phenotypic Groups in Patients with Stable Angina Pectoris after Treatment with Xinxuekang Capsule: A Randomized Controlled Trial
Current Vascular Pharmacology Resveratrol Targets in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel MicroRNA Signature to Differentiate Ulcerative Colitis from Crohn Disease: A Genome-Wide Study Using Next Generation Sequencing
MicroRNA Use of Cytokines in Cancer Vaccines/Immunotherapy: Recent Developments Improve Survival Rates for Patients with Metastatic Malignancy
Current Pharmaceutical Design Therapeutic Vaccines for Cervical Cancer: Dendritic Cell-Based Immunotherapy
Current Pharmaceutical Design Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Turning Tumor-Promoting Copper into an Anti-Cancer Weapon via High-Throughput Chemistry
Current Medicinal Chemistry Regulatory T Cells: Major Players in the Tumor Microenvironment
Current Pharmaceutical Design